TrialCancer immunology, immunotherapy : CII2013

Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.

Richard Harrop et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.